CN113166087B - 屏蔽剂及其用途 - Google Patents

屏蔽剂及其用途 Download PDF

Info

Publication number
CN113166087B
CN113166087B CN201980076992.7A CN201980076992A CN113166087B CN 113166087 B CN113166087 B CN 113166087B CN 201980076992 A CN201980076992 A CN 201980076992A CN 113166087 B CN113166087 B CN 113166087B
Authority
CN
China
Prior art keywords
cancer
imaging
compound
effective amount
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980076992.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113166087A (zh
Inventor
C·P·利蒙
I·R·弗拉霍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CN113166087A publication Critical patent/CN113166087A/zh
Application granted granted Critical
Publication of CN113166087B publication Critical patent/CN113166087B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006Esters of acyclic acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980076992.7A 2018-09-21 2019-09-19 屏蔽剂及其用途 Active CN113166087B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734690P 2018-09-21 2018-09-21
US62/734690 2018-09-21
PCT/US2019/051903 WO2020061293A1 (en) 2018-09-21 2019-09-19 Shielding agents and their use

Publications (2)

Publication Number Publication Date
CN113166087A CN113166087A (zh) 2021-07-23
CN113166087B true CN113166087B (zh) 2024-05-10

Family

ID=69887812

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980076992.7A Active CN113166087B (zh) 2018-09-21 2019-09-19 屏蔽剂及其用途

Country Status (5)

Country Link
US (1) US20210323985A1 (https=)
EP (1) EP3853213A4 (https=)
JP (2) JP7429688B2 (https=)
CN (1) CN113166087B (https=)
WO (1) WO2020061293A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015011118B1 (pt) * 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
CA3237590A1 (en) * 2021-11-09 2023-05-08 James Basilion Psma targeted conjugate compounds and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778910A (zh) * 2006-11-08 2010-07-14 分子制药洞察公司 谷氨酸的异质二聚体
CN103930432A (zh) * 2011-06-15 2014-07-16 癌靶技术有限责任公司 螯合的psma抑制剂
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN111801121A (zh) * 2017-04-11 2020-10-20 约翰霍普金斯大学 在psma靶向癌症成像或放疗期间用于健康组织保护的2-pmpa前药

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4464384A3 (en) 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
BR112015011118B1 (pt) * 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
US9988407B2 (en) 2014-08-06 2018-06-05 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
AU2015315465B2 (en) 2014-09-08 2019-08-29 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101778910A (zh) * 2006-11-08 2010-07-14 分子制药洞察公司 谷氨酸的异质二聚体
CN103930432A (zh) * 2011-06-15 2014-07-16 癌靶技术有限责任公司 螯合的psma抑制剂
WO2015055318A1 (en) * 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN111801121A (zh) * 2017-04-11 2020-10-20 约翰霍普金斯大学 在psma靶向癌症成像或放疗期间用于健康组织保护的2-pmpa前药

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for Pet Imaging;Eder, M; 等人;《Bioconjugate Chemistry》;第23卷(第4期);688-697 *

Also Published As

Publication number Publication date
JP2022501383A (ja) 2022-01-06
JP7429688B2 (ja) 2024-02-08
EP3853213A1 (en) 2021-07-28
EP3853213A4 (en) 2022-07-06
US20210323985A1 (en) 2021-10-21
JP2024028840A (ja) 2024-03-05
JP7748438B2 (ja) 2025-10-02
WO2020061293A1 (en) 2020-03-26
CN113166087A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
CN113166087B (zh) 屏蔽剂及其用途
KR102902487B1 (ko) 에반스 블루 유도체의 화학적 접합체 및 전립선 암 표적화를 위한 방사선 치료 및 조영제로서의 용도
ES2960030T3 (es) Tratamiento de células cancerosas que sobreexpresan receptores de somatostatina utilizando derivados de ocreótido quelados con radioisótopos
JP7840115B2 (ja) 癌を治療する方法
AU2019345320B2 (en) Methods of treating cancer
CN101626787A (zh) 诊断的和治疗的环氧合酶-2结合配体
CN116217505B (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
JP2025503451A (ja) 炭酸脱水酵素ixリガンド
CN121909051A (zh) 靶向成纤维细胞活化蛋白的组合物及其使用方法
WO2026039503A1 (en) Fibroblast activation protein-targeted compositions and methods of use thereof
HK40047004A (en) Methods of treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant